Verification evidence is still being completed.
PDF / print export
FinVector
Kuopio, Finland
- Verified lead
- Matthias Krieger
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- Managing Director
- 2026 technical specialization
- Viral-Based Gene Therapy Manufacturing and CDMO Services
- Review cycle
- May 2026
- Full address
- Microkatu 1 S, FI-70210 Kuopio, Finland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official FinVector about-us page confirming Matthias Krieger as Managing Director.
- Editorial note
- FinVector's official leadership and manufacturing pages support a live Kuopio CDMO record under Matthias Krieger with cGMP and FDA-facing manufacturing claims.
Viral-Based Gene Therapy Manufacturing and CDMO Services
cGMP manufacturing, FDA-approved drug manufacturer
FinVector's official leadership and manufacturing pages support a live Kuopio CDMO record under Matthias Krieger with cGMP and FDA-facing manufacturing claims.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
FinVector's official leadership and manufacturing pages support a live Kuopio CDMO record under Matthias Krieger with cGMP and FDA-facing manufacturing claims.
- Lead
- Matthias Krieger (verified ↗)
- Address
- Microkatu 1 S, FI-70210 Kuopio, Finland (source ↗)
- Compliance
- cGMP manufacturing · FDA-approved drug manufacturer
- Last reviewed
- 21 Mar 2026 (2mo ago)
- Scale
- Clinical-to-commercial gene-therapy manufacturing
- Capabilities
- Gene Therapy CDMO Services · Viral Vector Drug Substance · Drug Product Manufacturing
- Founded
- 1999
- Headcount
- 201-500
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Matthias Krieger
Managing Director
Full addressMicrokatu 1 S, FI-70210 Kuopio, Finland
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official FinVector contact page listing the Microkatu 1 S Kuopio address.
Open sourceClinical-to-commercial gene-therapy manufacturing
Kuopio, Finland. Viral-Based Gene Therapy Manufacturing and CDMO Services. Review completed on 21 Mar 2026.
Fimea, EMA, FDA, and gene-therapy manufacturing oversight
cGMP manufacturing, FDA-approved drug manufacturer
Viral-Based Gene Therapy Manufacturing and CDMO Services
FinVector's official leadership and manufacturing pages support a live Kuopio CDMO record under Matthias Krieger with cGMP and FDA-facing manufacturing claims.
Editorial note
FinVector's official leadership and manufacturing pages support a live Kuopio CDMO record under Matthias Krieger with cGMP and FDA-facing manufacturing claims.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Gene Therapy CDMO Services
Viral Vector Drug Substance
Drug Product Manufacturing
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
cGMP manufacturing suites
Viral-vector production systems
Quality-control and release laboratories
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- VERIFIED ACTIVE 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- VERIFIED ACTIVE 2026
Verification history
Verification history
21 Mar 2026: Executive identity confirmed via official management disclosure.
21 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is FinVector located?
- FinVector operates from Microkatu 1 S, FI-70210 Kuopio, Finland, Kuopio, Finland.
- Who runs FinVector?
- FinVector is led by Matthias Krieger, Managing Director. Verified 21 Mar 2026.
- What certifications does FinVector hold?
- FinVector is documented under cGMP manufacturing, FDA-approved drug manufacturer.
- What does FinVector do?
- FinVector's official leadership and manufacturing pages support a live Kuopio CDMO record under Matthias Krieger with cGMP and FDA-facing manufacturing claims. Core capabilities: Gene Therapy CDMO Services, Viral Vector Drug Substance, Drug Product Manufacturing.
Editorial context
Related technical briefs
Briefs that name Kuopio as a covered market or city.